When people hear about breakthrough cancer treatment in a statement from a drug company it might seem can sound like they suddenly invented something amazing. That’s usually not how it works.
Most new treatments start with basic research funded by the NIH and the National Cancer Institute. That early funding helps scientists learn how diseases work and test new ideas long before any company is ready to spend big money.
mRNA technology is a good example. The science behind it was built over many years with public support, long before it became a household term.
Now look at pancreatic cancer. A personalized mRNA treatment called autogene cevumeran is being evaluated after surgery in patients with pancreatic cancer. The idea is to train the immune system to spot and attack any cancer cells left behind.
Early (Phase 1) results were promising enough that the work moved into a larger global Phase 2 trial sponsored by Genentech in collaboration with BioNTech (which is underway with hundreds of patients right now).
That’s the pattern we see again and again: public funding helps build the platform; private industry funds the bigger trials needed to bring treatments to market.
And here’s the twist. Kennedy is openly hostile to mRNA technology, and he ended federal support for mRNA-related projects.
The good news is that the earlier basic research found this technology has potential applications for a host of cancer treatments, including for post-surgery pancreatic cancer.
The results found from decades of public investment that already helped launch mRNA into cancer research means that Kennedy won’t be able to single-handedly kill these new therapies. Even if new mRNA cancer treatments make it through their clinical trials and Kennedy directs the FDA to not license the therapy because of his confirmation bias mentality – he will be gone in 2.5 years.
And one more thing… if the pancreatic cancer trials pan out, a lot of MAHA people who spent years attacking mRNA may suddenly decide they’re very much in favor of it (or pretend they were never against the technology).
Note: In an ominous twist this week, the president dismissed all members of the National Science Board, the independent body that sets policy for the National Science Foundation and advises Congress and the president on science and education.







